Special Issue

Molecular Alterations and Targeted Therapy in Gastric Cancer

Message from the Guest Editors

Gastric cancer is an aggressive tumor often diagnosed at advanced stages. Despite recent advancements in targeted therapies and our growing understanding of the molecular landscape of gastric cancer, patient prognosis remains poor. There is an urgent need to investigate novel biomarkers that can facilitate the stratification of patients according to their prognosis and treatment options.

This Special Issue seeks contributions that focus on the identification and validation of novel biomarkers for gastric cancer. We welcome submissions that advance the field of gastric cancer research and provide insights into potential clinical applications. Topics of interest include, but are not limited to, the following:

- Genetic and epigenetic alterations;
- Proteomic and metabolomic profiling;
- Liquid biopsy:
- Predictive markers for treatment response;
- Prognostic markers for patient stratification;
- Novel therapeutic targets and pathways;
- Novel therapeutic approaches.

We look forward to your submissions.

Guest Editors

Dr. María Jesús Fernández Aceñero

Departments of Medical Oncology and Surgical Pathology, Universidad Complutense de Madrid, 28040 Madrid, Spain

Dr. Cristina Díaz del Arco

Department of Pathology, Hospital Clínico San Carlos, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain

Deadline for manuscript submissions

closed (15 May 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/206052

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

